336 related articles for article (PubMed ID: 3928681)
41. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans.
Mitchell TG; Friedman L
Infect Immun; 1972 Apr; 5(4):491-8. PubMed ID: 4564677
[TBL] [Abstract][Full Text] [Related]
42. Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.
Small JM; Mitchell TG
Infect Immun; 1986 Dec; 54(3):742-50. PubMed ID: 3536747
[TBL] [Abstract][Full Text] [Related]
43. Opsonization and phagocytosis of Cryptococcus neoformans.
Kozel TR
Arch Med Res; 1993; 24(3):211-8. PubMed ID: 8298269
[TBL] [Abstract][Full Text] [Related]
44. Virulence factors of Cryptococcus neoformans.
Hamilton AJ; Goodley J
Curr Top Med Mycol; 1996 Dec; 7(1):19-42. PubMed ID: 9504057
[TBL] [Abstract][Full Text] [Related]
45. Complementation of a capsule deficient Cryptococcus neoformans with CAP64 restores virulence in a murine lung infection.
Wilder JA; Olson GK; Chang YC; Kwon-Chung KJ; Lipscomb MF
Am J Respir Cell Mol Biol; 2002 Mar; 26(3):306-14. PubMed ID: 11867339
[TBL] [Abstract][Full Text] [Related]
46. Cryptococcus neoformans capsular polysaccharides form branched and complex filamentous networks viewed by high-resolution microscopy.
Araújo GR; Fontes GN; Leão D; Rocha GM; Pontes B; Sant'Anna C; de Souza W; Frases S
J Struct Biol; 2016 Jan; 193(1):75-82. PubMed ID: 26655746
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
48. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule.
Park YD; Shin S; Panepinto J; Ramos J; Qiu J; Frases S; Albuquerque P; Cordero RJ; Zhang N; Himmelreich U; Beenhouwer D; Bennett JE; Casadevall A; Williamson PR
PLoS Pathog; 2014 May; 10(5):e1004037. PubMed ID: 24789368
[TBL] [Abstract][Full Text] [Related]
49. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
Li RK; Mitchell TG
J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525
[TBL] [Abstract][Full Text] [Related]
50. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages.
Chrisman CJ; Albuquerque P; Guimaraes AJ; Nieves E; Casadevall A
PLoS Pathog; 2011 May; 7(5):e1002047. PubMed ID: 21637814
[TBL] [Abstract][Full Text] [Related]
51. Cryptococcus neoformans can form titan-like cells in vitro in response to multiple signals.
Trevijano-Contador N; de Oliveira HC; García-Rodas R; Rossi SA; Llorente I; Zaballos Á; Janbon G; Ariño J; Zaragoza Ó
PLoS Pathog; 2018 May; 14(5):e1007007. PubMed ID: 29775477
[TBL] [Abstract][Full Text] [Related]
52. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans.
Luberto C; Martinez-Mariño B; Taraskiewicz D; Bolaños B; Chitano P; Toffaletti DL; Cox GM; Perfect JR; Hannun YA; Balish E; Del Poeta M
J Clin Invest; 2003 Oct; 112(7):1080-94. PubMed ID: 14523045
[TBL] [Abstract][Full Text] [Related]
53. Effect of hypertonic solutes upon the polysaccharide capsule in Cryptococcus neoformans.
Jacobson ES; Tingler MJ; Quynn PL
Mycoses; 1989 Jan; 32(1):14-23. PubMed ID: 2664504
[TBL] [Abstract][Full Text] [Related]
54. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans.
Jacobson ES; Compton GM
J Med Vet Mycol; 1996; 34(4):289-91. PubMed ID: 8873890
[TBL] [Abstract][Full Text] [Related]
55. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
Laxalt KA; Kozel TR
Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
[TBL] [Abstract][Full Text] [Related]
56. The volume and hydration of the Cryptococcus neoformans polysaccharide capsule.
Maxson ME; Cook E; Casadevall A; Zaragoza O
Fungal Genet Biol; 2007 Mar; 44(3):180-6. PubMed ID: 16963294
[TBL] [Abstract][Full Text] [Related]
57. An ultrastructural examination of the interaction between macrophages and Cryptococcus neoformans.
Papadimitriou JM; Robertson TA; Kletter Y; Aronson M; Walters MN
J Pathol; 1978 Feb; 124(2):103-9. PubMed ID: 363987
[TBL] [Abstract][Full Text] [Related]
58. Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans.
Jain N; Li L; Hsueh YP; Guerrero A; Heitman J; Goldman DL; Fries BC
Infect Immun; 2009 Jan; 77(1):128-40. PubMed ID: 18955480
[TBL] [Abstract][Full Text] [Related]
59. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide.
Kozel TR
Infect Immun; 1977 Apr; 16(1):99-106. PubMed ID: 326680
[TBL] [Abstract][Full Text] [Related]
60. Capsule and melanin synthesis in Cryptococcus neoformans.
McFadden DC; Casadevall A
Med Mycol; 2001; 39 Suppl 1():19-30. PubMed ID: 11800266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
